Clinical Trial Update: Study of Cemiplimab in Adults With Cervical Cancer [Phase 3]

View source ↗

Summary

Phase 3 study update of cemiplimab in adults with cervical cancer (recurrent/metastatic, platinum-refractory); results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Squamous Cell Carcinoma

Drugs mentioned

• Cemiplimab (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-04-06